197
Participants
Start Date
October 31, 2011
Primary Completion Date
July 31, 2013
Study Completion Date
July 31, 2013
Pregabalin
Pregabalin 300 or 450 mg/day dosed BID ( twice a day) for 14 weeks; 150 mg/day starting dose
placebo
placebo capsules twice a day for 14 weeks
Social Psychiatry Research Institute, Brooklyn
Hospital General Universitario de Guadalajara, Guadalajara
Behavioral Medicine Center, Wyomissing
Clinical Research Center of Reading, LLP, Wyomissing
Azienda Ospedaliera Luigi Sacco - Polo Universitario, Milan
Charlottesville Medical Research, Charlottesville
Hospital General Universitario Gregorio Marañon, Madrid
Coastal Carolina Research Center, Mt. Pleasant
Medical Research and Health Education Foundation, Inc., Columbus
Florida Medical Center & Research, Inc., Coral Gables
Meridien Research, Tampa
Innovative Research of West Florida, Inc., Clearwater
Central Kentucky Research Associates, Inc., Lexington
Radiant Research, Inc., Columbus
University of Cincinnati, Cincinnati
Midwest Clinical Research Center, Dayton
Michigan Head Pain and Neurological Institute, Ann Arbor
Heartland Research Associates, LLC, Wichita
Quality Clinical Research, Inc., Omaha
FutureSearch Trials of Neurology, Austin
Fatigue Consultation Clinic, Salt Lake City
Lifetree Clinical Research, LC, Salt Lake City
Genova Clinical Research, Tucson
Research Across America, Santa Ana
SDS Clinical Trials, Orange
Sunstone Medical Research, LLC, Medford
Boston Clinical Trials, Boston
Coastal Medical, East Greenwich
Omega Medical Research, Warwick
Dr. Alexander McIntyre Inc., Penticton
Canadian Centre for Clinical Trials, Thornhill
Diex Research Sherbrooke Inc., Sherbrooke
"Università degli Studi di Roma La Sapienza", Roma
Hospital de lˊEsperança, Barcelona
Instituto Universitario USP Dexeus, Barcelona
Servicio de Reumatologia,Institut Ferran de Reumatologia-Clinica CIMA, Barcelona
Hospital Clínic de Barcelona, Barcelona
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
INDUSTRY